Azelastine Hcl

證據等級: L5

預測適應症: 0 個

Azelastine HCl: Evidence Pack Incomplete — Indicative Report Only

⚠️ Important Notice: This Evidence Pack is critically incomplete. The predicted_indications array is empty, meaning TxGNN has not returned any repurposing predictions for this drug. The following report reflects only what could be extracted from the available data. This report should not be used for any clinical or commissioning decision.

One-Sentence Summary

Azelastine HCl is a second-generation antihistamine (H1 receptor antagonist) commonly used for allergic rhinitis and allergic conjunctivitis. However, the TxGNN model has not returned any predicted new indications for this candidate in the current Evidence Pack. As a result, no repurposing analysis, evidence grading, or decision recommendation can be generated at this time.

Quick Overview

Item	Content
Original Indication	Not recorded in Evidence Pack
Predicted New Indication	None — prediction data absent
TxGNN Prediction Score	Not available
Evidence Level	Not determinable
UK Market Status	Not recorded in Evidence Pack
Number of Marketing Authorisations	0 recorded in Evidence Pack
Recommended Decision	Hold — insufficient data to proceed

Why the Report Cannot Be Completed

The Evidence Pack for Azelastine HCl contains two blocking or high-severity data gaps that prevent a full evaluation:

DG001 — Safety Warnings and Contraindications (Severity: Blocking) No SmPC-equivalent warnings or contraindications were retrieved. Without this, the standard safety screening (S1) cannot be completed. Remediation: Retrieve the product SmPC from the MHRA product listings and parse relevant sections.

DG002 — Mechanism of Action (Severity: High) No MOA data was retrieved from DrugBank (DrugBank ID not resolved). This prevents any mechanistic rationale from being constructed for a repurposing hypothesis. Remediation: Query DrugBank API using the INN “azelastine hydrochloride” and retrieve the pharmacology section.

Additionally, the predicted_indications field in the Evidence Pack is empty ([]). This is the most critical gap: without at least one TxGNN prediction, no indication-specific analysis (clinical trials, literature review, safety in new indication, cytotoxicity assessment) can be generated.

Safety Considerations

All safety fields in this Evidence Pack are unpopulated.

Please refer to the current SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack lacks predicted indications, a resolved DrugBank ID, MOA data, and safety information. There is no basis on which to evaluate a repurposing hypothesis.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for Azelastine HCl to populate predicted_indications; verify that the drug node exists in the knowledge graph under this INN or an accepted synonym (e.g., “azelastine”)
Resolve DrugBank ID — query DrugBank API or manually look up DB00453; update drug.drugbank_id in the Evidence Pack
Retrieve MOA from DrugBank pharmacology section and populate drug.original_moa
Retrieve UK market authorisations from the MHRA Product Licence database (https://products.mhra.gov.uk/) — note that Azelastine is understood to have licensed products in the UK (e.g., nasal spray and eye drop formulations); the current Evidence Pack appears to under-report this
Retrieve SmPC safety data (warnings, contraindications, interactions) and populate safety fields
Re-generate Evidence Pack at version v5+ and resubmit for report generation

This report was generated on 2026-04-04. It is based solely on the Evidence Pack provided and does not incorporate independent clinical judgement. Results are for research reference only and do not constitute medical advice.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.